Main Purpose: 

 

This study will look at drug levels in the blood over time and the safety of a single injection of a new investigational medicine that combines existing short-acting oral drugs used to treat HIV.

 

Main Requirements:

• Healthy adults between the ages of 18-65, all genders

• NO HIV, no active hepatitis B, no active hepatitis C

• Non-smokers or former smokers (quit >1 year ago)

• Low risk for HIV infection

• Not taking ANY prescription or over the counter medications (that cannot be safely stopped)

• No active drug or alcohol abuse

• If use cannabis, willing to stop cannabis use for 2 weeks before and during study

• Body Mass Index (BMI) less than 30

• Women of non-child-bearing potential
  (Either no sex with men, or post-menopause or copper IUD or hysterectomy or tubal ligation or ovaries removed) (Hormones of any type are exclusions.)

• Persons of child-bearing potential must use 2 of the following types of contraceptives throughout the study:

  • Condom (male or female)

  • Diaphragm or cervical cap

  • Copper-based intrauterine device

  • Vasectomy in the male partner

• No tattoos on abdomen near the belly-button

 

Length of Study (per person): 

Approximately 2 Months

 

Schedule of Study Appointments:

Screening, Entry, Days 1, 2, 3, 7, 10, 14, 21, 28, 35, 49 and 57

(Entry visits may last from 9 hours to 3 days. Most other on-study visits will take 30-60 min.)

 

Medications administered during study:  

1 subcutaneous injection of a combination of low doses of lopinavir, ritonavir and tenofovir

 

Study Procedures:  

Medical histories, Physical exams, Blood draws.

Some participants will have a lymph node biopsy

 

Reimbursement:  

$440-$1240 (plus $150 if have a lymph node biopsy)

​

Contact: 

Call or text us 206-773-7129